<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BUPAP- butalbital and acetaminophen tablet </strong><br>ECR Pharmaceuticals<br></p></div>
<h1>
<span class="Bold">Butalbital and Acetaminophen Tablets</span><br><span class="Bold">50 mg/300 mg</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4762d89c-18bf-4b67-aa26-9d821a93cbe9"></a><a name="section-1"></a><p></p>
<h1>BOXED WARNING</h1>
<div class="Warning">
<a name="id_2800662b-b78c-46ea-86aa-83537135d7ad"></a><a name="section-1.1"></a><p></p>
<h2>Hepatotoxicity</h2>
<p class="First">Acetaminophen has been associated with cases of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>, at times resulting in liver transplant and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Most of the cases of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_98d0d025-50ca-410d-bb0f-ad08ea11d08c"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each BUPAP Tablet for oral administration, contains Butalbital, USP 50 mg, Acetaminophen, USP 300 mg.</p>
<p>In addition each BUPAP Tablet contains the following inactive ingredients: Pregelatinized Starch, Microcrystalline Cellulose, Croscarmellose Sodium, Magnesium Stearate, D&amp;C Yellow #10 Lake, and FD&amp;C Red #40 Lake.</p>
<p>Butalbital (5-allyl-5-isobutylbarbituric acid), a slightly bitter, white, odorless, crystalline powder, is a short to intermediate-acting barbiturate. It has the following structural formula:</p>
<div class="Figure">
<a name="id250"></a><img alt="Butalbital Molecule" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30e483da-eaf1-4c73-9fed-333337f9ba86&amp;name=f68de00f-9150-4620-8e66-a319284ab192-01.jpg"><p class="MultiMediaCaption">C<span class="Sub">11</span>H<span class="Sub">16</span>N<span class="Sub">2</span>O<span class="Sub">3</span> M.W. =224.26 </p>
</div>
<p>C<span class="Sub">11</span>H<span class="Sub">16</span>N<span class="Sub">2</span>O<span class="Sub">3</span> M.W. =224.26 </p>
<p>Acetaminophen (4'-hydroxyacetanilide), a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic. It has the following structural formula:</p>
<div class="Figure">
<a name="id253"></a><img alt="APAP Molecule" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30e483da-eaf1-4c73-9fed-333337f9ba86&amp;name=f68de00f-9150-4620-8e66-a319284ab192-02.jpg"><p class="MultiMediaCaption">C<span class="Sub">8</span>H<span class="Sub">9</span>NO<span class="Sub">2</span> M.W. =151.16 </p>
</div>
<p>C<span class="Sub">8</span>H<span class="Sub">9</span>NO<span class="Sub">2</span> M.W. =151.16 </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_7b7bce67-d685-4640-a4aa-25bd0c9fead4"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">This combination drug product is intended as a treatment for <span class="product-label-link" type="condition" conceptid="376382" conceptname="Tension-type headache">tension headache</span>.</p>
<p>It consists of a fixed combination of butalbital and acetaminophen. The role each component plays in the relief of the complex of symptoms known as <span class="product-label-link" type="condition" conceptid="376382" conceptname="Tension-type headache">tension headache</span> is incompletely understood.</p>
<p>Pharmacokinetics: The behavior of the individual components is described below.</p>
<p>Butalbital: Butalbital is well absorbed from the gastrointestinal tract and is expected to distribute to most tissues in the body. Barbiturates in general may appear in breast milk and readily cross the placental barrier. They are bound to plasma and tissue proteins to a varying degree and binding increases directly as a function of lipid solubility.</p>
<p>Elimination of butalbital is primarily via the kidney (59% to 88% of the dose) as unchanged drug or metabolites. The plasma half-life is about 35 hours. Urinary excretion products include parent drug (about 3.6% of the dose), 5-isobutyl-5-(2,3-dihydroxy-propyl) barbituric acid (about 24% of the dose), 5-allyl-5 (3-hydroxy-2-methyl-1-propyl) barbituric acid (about 4.8% of the dose), products with the barbituric acid ring hydrolyzed with excretion of urea (about 14% of the dose), as well as unidentified materials. Of the material excreted in the urine, 32% is conjugated.</p>
<p>See<span class="Bold"><a href="#i4i_overdosage_id_616f5d29-02ef-4736-94f8-726d0077a04d">OVERDOSAGE</a></span> for toxicity information.</p>
<p>Acetaminophen: Acetaminophen is rapidly absorbed from the gastrointestinal tract and is distributed throughout most body tissues. The plasma half-life is 1.25 to 3 hours, but may be increased by <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> and following overdosage. Elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites. Approximately 85% of an oral dose appears in the urine within 24 hours of administration, most as the glucuronide conjugate, with small amounts of other conjugates and unchanged drug.</p>
<p>See <span class="Bold"><a href="#i4i_overdosage_id_616f5d29-02ef-4736-94f8-726d0077a04d">OVERDOSAGE</a></span> for toxicity information.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_2308e084-42a4-4f6b-bc3e-33b40095fef4"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">BUPAP Tablets are indicated for the relief of the symptom complex of <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> (or muscle contraction) <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p>Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> is unavailable. Caution in this regard is required because butalbital is habitforming and potentially abusable.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_03ebaa12-55b2-4153-972f-77223f8650de"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This product is contraindicated under the following conditions:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> or intolerance to any component of this product.</dd>
<dt>•</dt>
<dd>Patients with <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_18dbd541-94cf-4791-ad34-c8065c305e35"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Butalbital is habit-forming and potentially abusable. Consequently, the extended use of this product is not recommended.</p>
<p><span class="Bold">Hepatotoxicity</span></p>
<p>Acetaminophen has been associated with cases of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>, at times resulting in liver transplant and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Most of the cases of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief or unknowingly take other acetaminophen-containing products.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span> is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.</p>
<p>Instruct patients to look for acetaminophen or APAP on package labels and not to use more than one product that contains acetaminophen. Instruct patients to seek medical attention immediately upon ingestion of more than 4000 milligrams of acetaminophen per day, even if they feel well.</p>
<p><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span></span></p>
<p>Rarely, acetaminophen may cause serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> such as <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span> (<span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">AGEP</span>), <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal. Patients should be informed about the signs of serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, and use of the drug should be discontinued at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/ <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span></span></p>
<p>There have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> associated with use of acetaminophen. Clinical signs included <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, mouth, and throat, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, There were infrequent reports of life-threatening <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> requiring emergency medical attention. Instruct patients to discontinue BUPAP Tablets immediately and seek medical care if they experience these symptoms. Do not prescribe BUPAP Tablets for patients with acetaminophen <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_5cb4a3c9-169b-406c-98b1-ada824d7f4ab"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_97b4580a-3697-429d-a557-44e096601333"></a><a name="section-7.1"></a><p></p>
<h2><span class="Italics">General</span></h2>
<p class="First">BUPAP Tablets should be prescribed with caution in certain special-risk patients, such as the elderly or debilitated, and those with severe impairment of renal or hepatic function, or acute abdominal conditions.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_70edfe9b-42cd-42c6-aa86-a0cd4904b921"></a><a name="section-7.2"></a><p></p>
<h2><span class="Italics">Information for patients</span></h2>
<p class="First">This product may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Such tasks should be avoided while taking this product.</p>
<p>Alcohol and other CNS depressants may produce an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, when taken with this combination product, and should be avoided.</p>
<p>Butalbital may be habit-forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.</p>
<p>• Do not take BUPAP Tablets if you are allergic to any of its ingredients.</p>
<p>• If you develop signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> such as a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span> stop taking BUPAP Tablets and contact your healthcare provider immediately.</p>
<p>• Do not take more than 4000 milligrams of acetaminophen per day. Call your doctor if you took more than the recommended dose.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_93f01eeb-6e28-49fd-a25f-e9abda89162e"></a><a name="section-7.3"></a><p></p>
<h2><span class="Italics">Laboratory tests</span></h2>
<p class="First">In patients with severe hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, effects of therapy should be monitored with serial liver and/or renal function tests.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_d3a4e203-a1c8-4a17-84c8-21d0deda955f"></a><a name="section-7.4"></a><p></p>
<h2><span class="Italics">Drug interactions</span></h2>
<p class="First">The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.</p>
<p>Butalbital and acetaminophen may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_2af71bb1-30c4-4976-9559-76b60f150030"></a><a name="section-7.5"></a><p></p>
<h2><span class="Italics">Drug/laboratory test interactions</span></h2>
<p class="First">Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_77992430-87bd-44b6-b0a5-59ec28116903"></a><a name="section-7.6"></a><p></p>
<h2><span class="Italics">Carcinogenesis, mutagenesis, impairment of fertility</span></h2>
<p class="First">No adequate studies have been conducted in animals to determine whether acetaminophen or butalbital have a potential for carcinogenesis, mutagenesis or impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_88bda78e-e524-4036-80a1-208b04bfee24"></a><a name="section-7.7"></a><p></p>
<h2><span class="Italics">Pregnancy</span></h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_315d7717-3675-4985-a0fc-0f1070005c51"></a><a name="section-7.7.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Teratogenic effects</span></span></h3>
<p class="First">Pregnancy Category C: Animal reproduction studies have not been conducted with this combination product. It is also not known whether butalbital and acetaminophen can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. These products should be given to a pregnant woman only when clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_51c7ff1b-c38d-4b9e-ae1e-b2b67e1e21bc"></a><a name="section-7.7.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Nonteratogenic effects</span></span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4218977" conceptname="Drug withdrawal seizure">Withdrawal seizures</span> were reported in a two-day-old male infant whose mother had taken a butalbital-containing drug during the last two months of pregnancy. Butalbital was found in the infant's serum. The infant was given phenobarbital 5 mg/kg, which was tapered without further <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> or other withdrawal symptoms.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_a55e7b12-01d0-440f-8c3b-3b82fc675aab"></a><a name="section-7.8"></a><p></p>
<h2><span class="Italics">Nursing mothers</span></h2>
<p class="First">Barbiturates and acetaminophen are excreted in breast milk in small amounts, but the significance of their effects on nursing infants is not known. Because of potential for serious adverse reactions in nursing infants from butalbital and acetaminophen, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_674f57f3-0398-4254-bab9-432557140a1d"></a><a name="section-7.9"></a><p></p>
<h2><span class="Italics">Pediatric use</span></h2>
<p class="First">Safety and effectiveness in children below the age of 12 have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_da7311da-e036-45c8-8fc5-1782101ba040"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Frequently Observed: The most frequently reported adverse reactions are <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and intoxicated feeling.</p>
<p>Infrequently Observed: All adverse events tabulated below are classified as infrequent.</p>
<p>Central Nervous: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, shaky feeling, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, heavy eyelids, high energy, hot spells, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">sluggishness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Mental confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> can also occur due to intolerance, particularly in elderly or debilitated patients, or due to overdosage of butalbital.</p>
<p>Autonomic Nervous: <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>.</p>
<p>Gastrointestinal: difficulty swallowing, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
<p>Cardiovascular: <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p>Musculoskeletal: <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span>, <span class="product-label-link" type="condition" conceptid="4214612" conceptname="Muscle fatigue">muscle fatigue</span>.</p>
<p>Genitourinary: <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>.</p>
<p>Miscellaneous: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</p>
<p>Several cases of dermatological reactions, including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, have been reported.</p>
<p>The following adverse drug events may be borne in mind as potential effects of the components of this product. Potential effects of high dosage are listed in the <span class="Bold"><a href="#i4i_overdosage_id_616f5d29-02ef-4736-94f8-726d0077a04d">OVERDOSAGE</a></span> section. </p>
<p>Acetaminophen: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_58e7de68-47a0-4938-b893-61bc7793f123"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>: Butalbital: Barbiturates may be habit-forming: Tolerance, psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> may occur especially following prolonged use of high doses of barbiturates. The average daily dose for the barbiturate addict is usually about 1500 mg. As tolerance to barbiturates develops, the amount needed to maintain the same level of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> increases; tolerance to a fatal dosage, however, does not increase more than two-fold. As this occurs, the margin between an <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> dosage and fatal dosage becomes smaller. The lethal dose of a barbiturate is far less if alcohol is also ingested. Major withdrawal symptoms (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>) may occur within 16 hours and last up to 5 days after abrupt cessation of these drugs. Intensity of withdrawal symptoms gradually declines over a period of approximately 15 days. Treatment of barbiturate <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> consists of cautious and gradual withdrawal of the drug. Barbiturate-dependent patients can be withdrawn by using a number of different withdrawal regimens. One method involves initiating treatment at the patient's regular dosage level and gradually decreasing the daily dosage as tolerated by the patient.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_616f5d29-02ef-4736-94f8-726d0077a04d"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Following an acute overdosage of butalbital and acetaminophen, toxicity may result from the barbiturate or the acetaminophen.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_11f3eb1f-311f-41b4-8c9f-469ff7e808f9"></a><a name="section-10.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">Toxicity from barbiturate <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; and <span class="product-label-link" type="condition" conceptid="4192647" conceptname="Hypovolemic shock">hypovolemic shock</span>.</p>
<p>In acetaminophen overdosage: dose-dependent, potentially fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> is the most serious adverse effect. Renal tubular necroses, <span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">hypoglycemic coma</span>, and coagulation defects may also occur. Early symptoms following a potentially hepatotoxic <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e218702c-dc8d-4f8f-8d72-687fcd028ac1"></a><a name="section-10.2"></a><p></p>
<h2>Treatment:</h2>
<p class="First">A single or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdose</span> with these combination products is a potentially lethal polydrug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, and consultation with a regional poison control center is recommended. Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered.</p>
<p>Gastric decontamination with activated charcoal should be administered just prior to N-acetylcysteine (NAC) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation. Serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading. To obtain the best possible outcome, NAC should be administered as soon as possible where impending or evolving <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is suspected. Intravenous NAC may be administered when circumstances preclude oral administration.</p>
<p>Vigorous supportive therapy is required in severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_6b6c0077-be52-4457-bf22-4c8f931ec39e"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">BUPAP Tablets: One or two tablets every four hours. Total daily dosage should not exceed 6 tablets.</p>
<p>Extended and repeated use of these products is not recommended because of the potential for physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_49c34341-8eef-4274-a856-48bf34b9838b"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Yellowish round, unscored tablets with <span class="Bold">BA 300</span> on one side and plain on the other, in bottles of 100 (NDC 0095-3000-01) and in unit dose sample pouches for patient trial available only through physician offices (NDC 0095-3000-09). Each tablet contains butalbital, USP 50 mg and acetaminophen, USP 300 mg.</p>
<p>Store at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]. </p>
<p>Dispense in a tight container as defined in the USP.</p>
<p><span class="Bold">For Medical Information or to report Adverse events</span></p>
<p><span class="Bold">Phone 1-800-527-1955</span></p>
<p>Manufactured for:</p>
<p>ECR Pharmaceuticals</p>
<p>Richmond, VA 23255</p>
<p><a href="http://www.ecrpharma.com">www.ecrpharma.com</a></p>
<p>7075</p>
<p>Rev. 11/13</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_06ac2fb8-74eb-410b-b2a3-c835530a98d6"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL-100 Tablets</h1>
<div class="Figure">
<a name="id537"></a><img alt="Bupap Carton Image - 100 tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30e483da-eaf1-4c73-9fed-333337f9ba86&amp;name=f68de00f-9150-4620-8e66-a319284ab192-03.jpg">
</div>
<p class="First"><span class="Bold">NDC 0095-3000-01</span></p>
<p><span class="Bold">100 Tablets</span></p>
<p><span class="Bold">BUPAP®</span></p>
<p><span class="Bold">Butalbital/Acetaminophen Tablets</span></p>
<p><span class="Bold">50 mg/300 mg</span></p>
<p><span class="Bold">Each Tablet Contains:</span></p>
<p>Butalbital, USP* …… 50 mg</p>
<p><span class="Bold">*Warning: </span>May be habit-forming</p>
<p>Acetaminophen, USP …… 300 mg</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">ECR PHARMACEUTICALS</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BUPAP 		
					</strong><br><span class="contentTableReg">butalbital and acetaminophen tablets tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0095-3000</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BUTALBITAL</strong> (BUTALBITAL) </td>
<td class="formItem">BUTALBITAL</td>
<td class="formItem">50 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ACETAMINOPHEN</strong> (ACETAMINOPHEN) </td>
<td class="formItem">ACETAMINOPHEN</td>
<td class="formItem">300 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (YELLOWISH) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">BA;300</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0095-3000-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0095-3000-09</td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090956</td>
<td class="formItem">06/24/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>ECR Pharmaceuticals
							(831116350)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Nexgen Pharma, Inc</td>
<td class="formItem"></td>
<td class="formItem">160356114</td>
<td class="formItem">MANUFACTURE(0095-3000)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5076f608-70b9-4786-b33c-0bba73be6e63</div>
<div>Set id: 30e483da-eaf1-4c73-9fed-333337f9ba86</div>
<div>Version: 7</div>
<div>Effective Time: 20140825</div>
</div>
</div> <div class="DistributorName">ECR Pharmaceuticals</div></p>
</body></html>
